Cole H. Pieroni
Research Subjects
Research Interests
Cole H. Pieroni has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin J. Murdock
Department of Neurology University of Michigan Ann Arbor Michigan USA
1 shared publication - Bernard Boateng1 shared publication
- Caroline E. Piecuch
Department of Neurology, University of Michigan, Ann Arbor, MI, United States of America
1 shared publication - Carter Colwell
Virginia Tech Carilion School of Medicine, Roanoke, Virginia; Department of General Surgery, Carilion Clinic, Roanoke, Virginia
1 shared publication Esmaeel Dadashzadeh
1 shared publication- Eva Feldman
Department of Neurology, University of Michigan, Ann Arbor, USA
1 shared publication
Latest Publications
- Open Access
- 20 November 2025
- Published by Elsevier in Annals of Vascular Surgery - Brief Reports and Innovations
- Vol. 5 (4)
Endovascular treatment of superior vena cava syndrome utilizing an iliac branch endoprosthesis
- 20 November 2025
- Published by Elsevier in Annals of Vascular Surgery - Brief Reports and Innovations
- Vol. 5 (4)
Open AccessEndovascular treatment of superior vena cava syndrome utilizing an iliac branch endoprosthesis
- Open Access
- 8 June 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (11)
NK cells associate with ALS in a sex- and age-dependent manner
NK cells are innate immune cells implicated in ALS; whether NK cells impact ALS in a sex- and age-specific manner was investigated. Herein, NK cells were depleted in male and female SOD1 G93A ALS mice, survival and neuroinflammation were assessed, and data were stratified by sex. NK cell depletion extended survival in female but not male ALS mice with sex-specific effects on spinal cord microglia. In humans, NK cell numbers, NK cell subpopulations, and NK cell surface markers were examined in prospectively blood collected from subjects with ALS and control subjects; longitudinal changes in these metrics were correlated to revised ALS functional rating scale (ALSFRS-R) slope and stratified by sex and age. Expression of NK cell trafficking and cytotoxicity markers was elevated in subjects with ALS, and changes in CXCR3 + NK cells and 7 trafficking and cytotoxicity markers (CD11a, CD11b, CD38, CX3CR1, NKG2D, NKp30, NKp46) correlated with disease progression. Age affected the associations between ALSFRS-R and markers NKG2D and NKp46, whereas sex impacted the NKp30 association. Collectively, these findings suggest that NK cells contribute to ALS progression in a sex- and age-specific manner and demonstrate that age and sex are critical variables when designing and assessing ALS immunotherapy.
- 8 June 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (11)
Open AccessNK cells associate with ALS in a sex- and age-dependent manner
NK cells are innate immune cells implicated in ALS; whether NK cells impact ALS in a sex- and age-specific manner was investigated. Herein, NK cells were depleted in male and female SOD1 G93A ALS mice, survival and neuroinflammation were assessed, and data were stratified by sex. NK cell depletion extended survival in female but not male ALS mice with sex-specific effects on spinal cord microglia. In humans, NK cell numbers, NK cell subpopulations, and NK cell surface markers were examined in prospectively blood collected from subjects with ALS and control subjects; longitudinal changes in these metrics were correlated to revised ALS functional rating scale (ALSFRS-R) slope and stratified by sex and age. Expression of NK cell trafficking and cytotoxicity markers was elevated in subjects with ALS, and changes in CXCR3 + NK cells and 7 trafficking and cytotoxicity markers (CD11a, CD11b, CD38, CX3CR1, NKG2D, NKp30, NKp46) correlated with disease progression. Age affected the associations between ALSFRS-R and markers NKG2D and NKp46, whereas sex impacted the NKp30 association. Collectively, these findings suggest that NK cells contribute to ALS progression in a sex- and age-specific manner and demonstrate that age and sex are critical variables when designing and assessing ALS immunotherapy.